An indigenous biotechnology start-up, Syndicate Bio, has joined forces with SophiaGenetics, a leading cloud-native software firm in data-driven medicine, to establish the first-ever laboratory in Africa offering comprehensive genomic profiling and liquid biopsy services.
This groundbreaking collaboration signifies a pivotal moment in Africa’s healthcare evolution, promising unparalleled access to state-of-the-art genomic technologies that were previously out of reach for patients across the continent.
By harnessing Sophia Genetics’ proficiency in cloud-based healthcare solutions, Syndicate Bio is set on a mission to democratize genetic testing and equip healthcare providers with advanced diagnostic tools.
The alliance holds immense promise for enhancing cancer care in Africa, where the need for such advancements is dire.
Recent data from the World Health Organization underscores the urgency of this endeavor, with a staggering 1.1 million new cancer cases reported annually in Africa, leading to approximately 700,000 fatalities.
Without immediate interventions, projections indicate a bleak outlook, with cancer-related deaths expected to soar to nearly one million annually by 2030.
The establishment of this laboratory fills crucial gaps in diagnostic capabilities, particularly benefiting underserved individuals who previously had to seek testing outside the continent. Moreover, it marks a significant step towards reducing the burden of cancer and other diseases in Africa.
According to the Chief Medical Officer of SOPHiA Genetics, this partnership transcends immediate clinical impact. By leveraging the wealth of data generated, the collaboration aims to fuel innovation, expedite drug discovery, and ultimately elevate health outcomes on a global scale.
In October 2023, Syndicate Bio reaffirmed its commitment to advancing genomic research in Nigeria by entering into a Memorandum of Understanding (MoU) with the Nigerian Institute of Medical Research (NIMR). This strategic alliance is poised to drive transformative studies in infectious and non-infectious diseases, with a specific focus on addressing prevalent health challenges within Nigeria.
Central to this collaboration is NIMR’s role in ensuring ethical oversight, facilitated through its internal ethics body and the National Health Research Ethics Committee (NHREC). By leveraging NIMR’s expertise and infrastructure, Syndicate Bio aims to expedite the identification of potential drug targets, thus catalyzing innovation in healthcare solutions tailored to the unique needs of the Nigerian population.
